Selection of recombinant MVA by rescue of the essential D4R gene

Virology Journal

Volumn 8, Issue , 2011, Pages

  Ricci, Patricia S ^a   Schäfer, Birgit ^a   Kreil, Thomas R ^a   Falkner, Falko G ^a   Holzer, Georg W ^a  

^a BAXTER BIOSCIENCE   (Austria)

Author keywords

Cell Line; Defective viruses genetics; Defective viruses growth development; Recombinant vaccines; Transformed; Uracil DNA glycosylase; Vaccinia virus

Indexed keywords

MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; URACIL DNA GLYCOSIDASE; VIRUS PROTEIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DELETION MUTANT; EMBRYO; HOST RANGE; MARKER GENE; NONHUMAN; VACCINIA VIRUS; VIRUS GENE; VIRUS RECOMBINANT; VIRUS REPLICATION; WILD TYPE; ANIMAL; CELL LINE; CERCOPITHECUS; DNA REPLICATION; ESSENTIAL GENE; GENE DELETION; GENE VECTOR; GENETIC RECOMBINATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; METABOLISM; PATHOGENICITY; VERO CELL;

VACCINIA VIRUS; VACCINIA VIRUS ANKARA;

ANIMALS; CELL LINE; CERCOPITHECUS AETHIOPS; DNA REPLICATION; GENES, ESSENTIAL; GENES, VIRAL; GENETIC VECTORS; HUMANS; RECOMBINATION, GENETIC; SEQUENCE DELETION; URACIL-DNA GLYCOSIDASE; VACCINIA VIRUS; VERO CELLS; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 83155178475     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-529     Document Type: Article

References (44)

1. Abstammung, Eigenschaften und Verwendung des attenuierten Vaccinia-Stammes MVA. Mayr A, Hochstein-Mintzel V, Stickl H, Infection 1975 3 6 14 10.1007/BF01641272
2. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl). Mayr A, Stickl H, Muller HK, Danner K, Singer H, Zentralbl Bakteriol B 1978 167 375 390 219640 (Pubitemid 9145179)
3. MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl). Stickl H, Hochstein-Mintzel V, Mayr A, Huber HC, Schafer H, Holzner A, Dtsch Med Wochenschr 1974 99 2386 2392 10.1055/s-0028-1108143 4426258
4. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naive and vaccinia-immune individuals. Parrino J, McCurdy LH, Larkin BD, Gordon IJ, Rucker SE, Enama ME, Koup RA, Roederer M, Bailer RT, Moodie Z, Gu L, Yan L, Graham BS, Vaccine 2007 25 1513 1525 10.1016/j.vaccine.2006.10.047 17126963 (Pubitemid 46074296)
5. A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. von Krempelhuber A, Vollmar J, Pokorny R, Rapp P, Wulff N, Petzold B, Handley A, Mateo L, Siersbol H, Kollaritsch H, Chaplin P, Vaccine 2010 28 1209 1216 10.1016/j.vaccine.2009.11.030 19944151
6. Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration. Wilck MB, Seaman MS, Baden LR, Walsh SR, Grandpre LE, Devoy C, Giri A, Kleinjan JA, Noble LC, Stevenson KE, Kim HT, Dolin R, J Infect Dis 2010 201 1361 1370 10.1086/651561 20350191
7. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Antoine G, Scheiflinger F, Dorner F, Falkner FG, Virology 1998 244 365 396 10.1006/viro.1998.9123 9601507 (Pubitemid 28384101)
8. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. Meyer H, Sutter G, Mayr A, J Gen Virol 1991 72 Pt 5 1031 1038 2033387
9. Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential? Drexler I, Staib C, Sutter G, Curr Opin Biotechnol 2004 15 506 512 10.1016/j.copbio.2004.09.001 15560976 (Pubitemid 39551002)
10. A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects. Keefer MC, Frey SE, Elizaga M, Metch B, De Rosa SC, Barroso PF, Tomaras G, Cardinali M, Goepfert P, Kalichman A, Philippon V, McElrath MJ, Jin X, Ferrari G, Defawe OD, Mazzara GP, Montefiori D, Pensiero M, Panicali DL, Corey L, Vaccine 2011 29 1948 1958 10.1016/j.vaccine.2010.12.104 21216311
11. Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate. Currier JR, Ngauy V, de Souza MS, Ratto-Kim S, Cox JH, Polonis VR, Earl P, Moss B, Peel S, Slike B, Sriplienchan S, Thongcharoen P, Paris RM, Robb ML, Kim J, Michael NL, Marovich MA, PLoS One 2010 5 13983 10.1371/journal.pone.0013983 21085591
12. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Berthoud TK, Hamill M, Lillie PJ, Hwenda L, Collins KA, Ewer KJ, Milicic A, Poyntz HC, Lambe T, Fletcher HA, Hill AV, Gilbert SC, Clin Infect Dis 2011 52 1 7 10.1093/cid/ciq015 21148512
13. Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Amato RJ, Hawkins RE, Kaufman HL, Thompson JA, Tomczak P, Szczylik C, McDonald M, Eastty S, Shingler WH, de BJ, Goonewardena M, Naylor S, Harrop R, Clin Cancer Res 2010 16 5539 5547 10.1158/1078-0432.CCR-10-2082 20881001
14. Vaccinia virus: a selectable eukaryotic cloning and expression vector. Mackett M, Smith GL, Moss B, Proc Natl Acad Sci USA 1982 79 7415 7419 10.1073/pnas.79.23.7415 6296831 (Pubitemid 13179118)
15. Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Panicali D, Paoletti E, Proc Natl Acad Sci USA 1982 79 4927 4931 10.1073/pnas.79.16.4927 6289324
16. Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors. Falkner FG, Moss B, J Virol 1988 62 1849 1854 3130492
17. Vaccinia virus expression vector: Coexpression of beta-galactosidase provides visual screening of recombinant virus plaques. Chakrabarti S, Brechling K, Moss B, Mol Cell Biol 1985 5 3403 3409 3939316 (Pubitemid 16233047)
18. Transient host range selection for genetic engineering of modified vaccinia virus Ankara. Staib C, Drexler I, Ohlmann M, Wintersperger S, Erfle V, Sutter G, Biotechniques 2000 28 1137 6-1148 10868279
19. The vaccinia virus K1L gene product inhibits host NF-kappaB activation by preventing IkappaBalpha degradation. Shisler JL, Jin XL, J Virol 2004 78 3553 3560 10.1128/JVI.78.7.3553-3560.2004 15016878 (Pubitemid 38568297)
20. Viral host-range factor C7 or K1 is essential for modified vaccinia virus Ankara late gene expression in human and murine cells, irrespective of their capacity to inhibit protein kinase R-mediated phosphorylation of eukaryotic translation initiation factor 2alpha. Backes S, Sperling KM, Zwilling J, Gasteiger G, Ludwig H, Kremmer E, Schwantes A, Staib C, Sutter G, J Gen Virol 2010 91 470 482 10.1099/vir.0.015347-0 19846675
21. Modified vaccinia virus Ankara can activate NF-kappaB transcription factors through a double-stranded RNA-activated protein kinase (PKR)-dependent pathway during the early phase of virus replication. Lynch HE, Ray CA, Oie KL, Pollara JJ, Petty IT, Sadler AJ, Williams BR, Pickup DJ, Virology 2009 391 177 186 10.1016/j.virol.2009.06.012 19596385
22. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Sutter G, Wyatt LS, Foley PL, Bennink JR, Moss B, Vaccine 1994 12 1032 1040 10.1016/0264-410X(94)90341-7 7975844
23. Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L. Hornemann S, Harlin O, Staib C, Kisling S, Erfle V, Kaspers B, Hacker G, Sutter G, J Virol 2003 77 8394 8407 10.1128/JVI.77.15.8394-8407.2003 12857909 (Pubitemid 36871468)
24. Isolation of vaccinia MVA recombinants using the viral F13L gene as the selective marker. Sanchez-Puig JM, Blasco R, Biotechniques 2005 39 665 670 10.2144/000112012 16312215
25. Construction of a vaccinia virus deficient in the essential DNA repair enzyme uracil DNA glycosylase by a complementing cell line. Holzer GW, Falkner FG, J Virol 1997 71 4997 5002 9188564 (Pubitemid 27258169)
26. Vaccinia virus uracil DNA glycosylase has an essential role in DNA synthesis that is independent of its glycosylase activity: catalytic site mutations reduce virulence but not virus replication in cultured cells. De Silva FS, Moss B, J Virol 2003 77 159 166 10.1128/JVI.77.1.159-166.2003 12477821 (Pubitemid 36004956)
27. Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies. Garber DA, O'Mara LA, Zhao J, Gangadhara S, An I, Feinberg MB, PLoS One 2009 4 5445 10.1371/journal.pone. 0005445 19421328
28. The DF-1 chicken fibroblast cell line: transformation induced by diverse oncogenes and cell death resulting from infection by avian leukosis viruses. Himly M, Foster DN, Bottoli I, Iacovoni JS, Vogt PK, Virology 1998 248 295 304 10.1006/viro.1998.9290 9721238 (Pubitemid 28417716)
29. Dominant host range selection of vaccinia recombinants by rescue of an essential gene. Holzer GW, Gritschenberger W, Mayrhofer JA, Wieser V, Dorner F, Falkner FG, Virology 1998 249 160 166 10.1006/viro.1998.9307 9740787 (Pubitemid 28430917)
30. Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara. Ober BT, Bruhl P, Schmidt M, Wieser V, Gritschenberger W, Coulibaly S, Savidis-Dacho H, Gerencer M, Falkner FG, J Virol 2002 76 7713 7723 10.1128/JVI.76.15.7713-7723.2002 12097585 (Pubitemid 34760995)
31. Pre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow fever. Schaefer B, Holzer GW, Joachimsthaler A, Coulibaly S, Schwendinger M, Crowe BA, Kreil TR, Noel PN, Falkner FG, PLoS One 2011 6 24505 10.1371/journal.pone.0024505 21931732
32. Improved retroviral vectors for gene transfer and expression. Miller AD, Rosman GJ, Biotechniques 1989 7 980 989 2631796
33. A safe packaging line for gene transfer: separating viral genes on two different plasmids. Markowitz D, Goff S, Bank A, J Virol 1988 62 1120 1124 2831375 (Pubitemid 18082924)
34. Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection. Mayrhofer J, Coulibaly S, Hessel A, Holzer GW, Schwendinger M, Bruhl P, Gerencer M, Crowe BA, Shuo S, Hong W, Tan YJ, Dietrich B, Sabarth N, Savidis-Dacho H, Kistner O, Barrett PN, Falkner FG, J Virol 2009 83 5192 5203 10.1128/JVI.02081-08 19279103
35. A new technique for the assay of infectivity of human adenovirus 5 DNA. Graham FL, Van Der Eb AJ, Virology 1973 52 456 467 10.1016/0042-6822(73)90341-3 4705382
36. The purification fo four strains of poxvirus. Joklik WK, Virology 1962 18 9 18 10.1016/0042-6822(62)90172-1 14036977
37. Finney DJ, Statistical methods in biological assay London: Griffin 1 1952
38. Preparation of cell cultures and vaccinia virus stocks. Earl PL, Cooper N, Wyatt LS, Moss B, Carroll MW, Current Protocols in Molecular Biology John Wiley & Sons Inc. 1998 16.16.1 16.16.13
39. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Towbin H, Staehelin T, Gordon J, Proc Natl Acad Sci USA 1979 76 4350 4354 10.1073/pnas.76.9.4350 388439 (Pubitemid 9256559)
40. Characterization of the vaccinia MVA hemagglutinin gene locus and its evaluation as an insertion site for foreign genes. Antoine G, Scheiflinger F, Holzer G, Langmann T, Falkner FG, Dorner F, Gene 1996 177 43 46 10.1016/0378-1119(96)00267-3 8921843 (Pubitemid 26370759)
41. Transient marker stabilisation: a general procedure to construct marker-free recombinant vaccinia virus. Scheiflinger F, Dorner F, Falkner FG, Arch Virol 1998 143 467 474 10.1007/s007050050303 9572548 (Pubitemid 28167180)
42. Cloning the vaccinia virus genome as a bacterial artificial chromosome in Escherichia coli and recovery of infectious virus in mammalian cells. Domi A, Moss B, Proc Natl Acad Sci USA 2002 99 12415 12420 10.1073/pnas.192420599 12196634
43. Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA). Cottingham MG, Andersen RF, Spencer AJ, Saurya S, Furze J, Hill AV, Gilbert SC, PLoS One 2008 3 1638 10.1371/journal.pone.0001638 18286194 (Pubitemid 351865468)
44. Rapid generation of markerless recombinant MVA vaccines by en passant recombineering of a self-excising bacterial artificial chromosome. Cottingham MG, Gilbert SC, J Virol Methods 2010 168 233 236 10.1016/j.jviromet.2010.04.012 20417665